1 Introduction
2 Photodynamic and biochemical activation of survival pathways
2.1 ROS production through photosensitizer excitation
2.2 Mechanisms of cytotoxicity
2.2.1 PDT-induced oxidative stress
2.2.2 PDT-induced hypoxia
2.2.3 PDT-induced antitumor immune response
3 Survival pathways activated in tumor cells post-PDT
3.1 The NRF2 pathway
3.1.1 Activation mechanism of NRF2
3.1.2 Downstream effects of the NRF2 pathway
3.1.3 Role of the NRF2 pathway in PDT
3.1.4 Inhibition strategies for NRF2 and its downstream targets
Pathways | Target | Inhibitor | Mechanism | Reference |
---|---|---|---|---|
NRF2 | NRF2 | Retinoic acid (and analogs) | Inhibition of DNA- binding due to sequestration by RARα | [131] |
NRF2 | HO-1 | ZnPP | Nonreversible antagonist | [132] |
NRF2 | HO-1 | SnPPIX | Nonreversible antagonist | [133] |
NRF2 | Cu-SOD/Zn-SOD | DDC | Chelation of Cu(II) and Zn(II) | [167] |
NRF2 | Mn-SOD | 2-ME | Does not inhibit Mn-SOD but increases superoxide levels | [134] |
NRF2 | GCL | BSO | Nonreversible antagonist | [135] |
NRF2 | Catalase | 3-AT | Nonreversible antagonist | [136] |
NF-κB | RELA (NF-κB) | Parthenolide | Alkylation at Cys38, inhibition of DNA binding | [137] |
NF-κB | NF-κB | Panepoxydone | Inhibition of IκB phosphorylation | [138] |
NF-κB | NF-κB | Bay 11-7082 | Inhibition upstream of IKK | [139] |
NF-κB | NF-κB | DHMEQ | Inhibition of DNA binding and nuclear localization | [140] |
NF-κB | NF-κB | α-Ketoglutarate | Reactivation of PHD proteins | [141] |
NF-κB | COX-2 | NSAIDs (e.g., ibuprofen, celecoxib) | Reversible antagonist | [142] |
NF-κB | STAT3 | STA-21 | Inhibition of DNA binding | [143] |
NF-κB | STAT3 | WP1066 | Dephosphorylates STAT3 and causes nuclear export | [144] |
NF-κB | Survivin | LY218130B | RNAi | [145] |
NF-κB | Survivin | YM155 | Inhibition of transcription | [145] |
NF-κB | Survivin | Terameprocol (EM1421) | Inhibition of transcription | [145] |
NF-κB | IL-6/sIL-6R | sgp130Fc | Sequestration of sIL-6R | [146] |
NF-κB | MMP (broad spectrum) | Prinomastat | Chelation of Zn(II) in the catalytic domain | [147] |
HIF-1 | HIF-1 | Amphotericin B | Increased activity of FIH | [148] |
HIF-1 | HIF-1 | Echinomycin | Inhibition of DNA binding | [149] |
HIF-1 | HIF-1 | α-Ketoglutarate | Reactivation of PHD proteins | [141] |
HIF-1 | HIF-1 | Curcumin | Oxidation and proteasomal degradation of HIF-1β | [150] |
HIF-1 | HIF-1 | Acriflavine | Binding to HIF-1α dimerization domain | [151] |
ASK1 | AP-1 | Retinoic acid (and analogs) | Inhibition of DNA binding (does not involve RARα) | [152] |
ASK1 | JNK1 | SP600125 | Reversible ATP antagonist | [153] |
ASK1 | p38α/β | SB202190 | Reversible ATP antagonist | [154] |
ASK1 | p38α/β | Sb203580 | Reversible ATP antagonist | [154] |
ASK1 | p38α/β | PD169316 | Reversible ATP antagonist | [154] |
UPR | HSP90 | Geldanamycin (17-AAG) | ATP antagonist | [155] |
UPR | HSP90 | CNF2024/BIIB021 | ATP antagonist | [156] |
UPR | HSP90 | NVP-AUY922 | Complex formation with HSP70 | [157] |
UPR | HSP90 | SNX-5422 | ATP antagonist | [158] |
UPR | HSP90 | STA-9090 | ATP antagonist | [159] |
UPR | HSP70 | SubA | Antagonist | [160] |
UPR | HSP70 | VRS-155008 | ATP antagonist | [161] |
UPR | HSF1 | KRIBB11 | Inhibition of transcriptional activity | [127] |
UPR | Proteasome | Bortezomib | Antagonist of catalytic site | [162] |
UPR | IRE1/ATF6 | 4-Phenylbutyric acid (and analogs) | Unknown | [163] |
UPR | PERK | GSK-2656157 | APP antagonist | [164] |
3.1.5 Concluding remarks
3.2 The NF-κB pathway
3.2.1 Activation mechanisms of NF-κB
3.2.2 Downstream effects of the NF-κB pathway
3.2.3 Role of the NF-κB pathway in PDT
3.2.4 Inhibition strategies for NF-κB and its downstream targets
3.2.5 Concluding remarks
3.3 The HIF-1 pathway
3.3.1 Activation mechanisms of HIF-1
3.3.2 Downstream effects of the HIF-1 pathway
3.3.3 Role of the HIF-1 pathway in PDT
3.3.4 Inhibition strategies for HIF-1 and its downstream targets
3.3.5 Concluding remarks
3.4 The ASK1 pathway
3.4.1 Activation mechanisms of ASK1
3.4.2 Downstream effects of ASK1 activation
3.4.3 Role of the ASK1 pathway in PDT
3.4.4 Inhibition strategies of ASK1 and its downstream targets
Inhibitor | Dose (μM) | Cell type | Photosensitizer | Fluence | Light source | Outcome | Reference |
---|---|---|---|---|---|---|---|
PD169316 | 25 | HELA ovarian carcinoma | Hypericin (0.125 μM) | 4 J/cm2
| Not specified |
Inhibition of p38 induced apoptosis in JNK-inhibited cells
| [411] |
SEK-AL/TAM67 transfection |
Inhibition of JNK induced apoptosis
| ||||||
SB202190 | 15 | LYR mouse lymphoma | Pc4 (0.5 μM) | 3 J/cm2
| >600 nm |
Inhibition of p38α and β2 prevented apoptosis
| [412] |
SB202190 | 15 | CHO Chinese hamster ovary | Pc4 (0.5 μM) | 10 J/cm2
| >600 nm |
Inhibition of p38α and β2 prevented apoptosis
| |
PD169316 | 1 | T24 bladder cancer | Hypericin (0.15 μM) | 4 J/cm2
| 530–620 nm |
Inhibition of p38 induced apoptosis
| [244] |
Gene knockout | GM38A fibroblast | Photofrin (10 μg/mL) | 0.27 J/cm2
| 630 nm | Knockout of p38 had no effect | [413] | |
Gene knockout | LFS087 Li-Froumeni syndrome | Photofrin (7.5 μg/mL) | 0.27 J/cm2
| 630 nm | Knockout of JNK had no effect | ||
PD169316 | 1 | T24 cocultured human umbilical vein endothelial cells | Hypericin (0.15 μM) | 4 J/cm2
| 530–620 nm |
Inhibition of p38 prevented T24-cocultured HUVEC migration
| [243] |
PD169316 | 0.1 | MEF mouse embryonic fibroblasts | Hypericin (0.5 μM) | 2.7 J/cm2
| 530–620 nm |
Inhibition of p38 induced apoptosis
| |
PD169316 | 1 | T24 bladder cancer | Hypericin (0.15 μM) | 4 J/cm2
| 530–620 nm |
Inhibition of p38 induced apoptosis
| [85] |
SP600125 | 1 | Not reported | |||||
PD169316 | 1 | T24 bladder cancer | Hypericin (0.15 μM) | 4 J/cm2
| 530–620 nm |
Inhibition of p38 induced apoptosis
| [414] |
SB202190/SB203580 | 1 / 12 | RIF1 murine radiation- induced fibrosarcoma | Photofrin (25 μg/mL) | 315 J/cm2
| Not specified |
Inhibition of p38α and β2 induced apoptosis
| [202] |
SP600125 | 20 | Inhibition of JNK had no effect | |||||
SB203580 | 20 | NuTu-19 rat epithelial ovarian cancer | TPPS2A (2 μg/mL) | 1.35 J/cm2
| 435 nm |
Inhibition of p38α and β2 prevented apoptosis
| [415] |
SP600125 | 5 |
Inhibition of JNK induced apoptosis
| |||||
SB202190 | 10 | HK-1 nasopharyngeal squamous cell carcinoma | Hypericin (1 μM) | 0.2 J/cm2
| 590 nm |
Inhibition of p38α and β2 induced apoptosis
| [416] |
SB203580 | 10 |
Inhibition of p38α and β2 induced apoptosis
| |||||
SP600125 | 10 | Inhibition of JNK had no effect | |||||
SP600125 | 0.5 | HepG2 hepatocellular carcinoma | Pheophorbide a (0.75 μM) | 84 J/cm2
| 610 nm |
Inhibition of JNK prevented apoptosis
| [417] |
PD169316 | 2.5 | CNE-2 nasopharyngeal carcinoma | Zn-BC-AM (1 μM) | 1 J/cm2
| 682 nm |
Inhibition of p38 induced apoptosis
| [418] |
SB203580 | 10 |
Inhibition of p38α and β2 prevented apoptosis
| |||||
SP600125 | 5 | Inhibition of JNK had no effect | |||||
SB203580 | 10 | Ca9-22 oral cancer | ALA (1 mM) | 4 J/cm2
| 635 nm |
Inhibition of p38α and β2 induced apoptosis
| [275] |
SP600125 | 10 |
Inhibition of JNK prevented apoptosis
| |||||
PD169316 | 5 | T24 bladder cancer | Hypericin (0.15 μM) | 1.6 J/cm2
| White light |
Inhibition of p38 induced apoptosis
| [386] |
Gene knockout | MEF mouse embryonic fibroblasts | Hypericin (0.125 μM) | 0.4–0.8 J | White light |
Knockout of p38α induced apoptosis
| ||
SB203580 | 10 | MCF7 human mammary adenocarcinoma | Photofrin (5 μg/mL) | 0.36 J/cm2
| 635 nm |
Inhibition of p38α and β2 prevented COX-2 accumulation
| [170] |